4//SEC Filing
BALDO LANCE 4
Accession 0001209191-20-057799
CIK 0001478320other
Filed
Nov 9, 7:00 PM ET
Accepted
Nov 10, 9:00 PM ET
Size
11.3 KB
Accession
0001209191-20-057799
Insider Transaction Report
Form 4
BALDO LANCE
Chief Medical Officer
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2020-11-06−6,250→ 387,500 totalExercise: $7.80Exp: 2029-05-06→ Common Stock (6,250 underlying) - Exercise/Conversion
Common Stock
2020-11-06$7.80/sh+6,250$48,750→ 6,250 total - Sale
Common Stock
2020-11-06$50.54/sh−5,453$275,595→ 797 total - Sale
Common Stock
2020-11-06$51.26/sh−797$40,854→ 0 total
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2020.
- [F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $50.10 to 50.96, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $51.18 to 51.42, inclusive.
- [F4]The options vested with respect to 1/4 of the shares on May 6, 2020, with 1/48 of the shares vesting thereafter at the end of each full month of continuous service until fully vested.
Documents
Issuer
Adaptive Biotechnologies Corp
CIK 0001478320
Entity typeother
Related Parties
1- filerCIK 0001780773
Filing Metadata
- Form type
- 4
- Filed
- Nov 9, 7:00 PM ET
- Accepted
- Nov 10, 9:00 PM ET
- Size
- 11.3 KB